1 Chang, J. H. et al. Corneal neovascularization: an anti-VEGF therapy review. Surv Ophthalmol57, 415-429, doi:10.1016/j.survophthal.2012.01.007 (2012).
2 Sharif, Z. & Sharif, W. Corneal neovascularization: updates on pathophysiology, investigations & management. romanian journal of ophthalmology63, 15-22, doi:10.22336/rjo.2019.4 (2019).
3 Foster, A. & Resnikoff, S. The impact of Vision 2020 on global blindness. k 0 Eye (Lond)19, 1133-1135, doi:10.1038/sj.eye.6701973 (2005).
4 Lee, P., Wang, C. C. & Adamis, A. P. Ocular neovascularization: an epidemiologic review. Surv Ophthalmol43, 245-269, doi:10.1016/s0039-6257(98)00035-6 (1998).
5 Bachmann, B. O. et al. Promotion of graft survival by vascular endothelial growth factor a neutralization after high-risk corneal transplantation. Arch Ophthalmol126, 71-77, doi:10.1001/archopht.126.1.71 (2008).
6 Cursiefen, C. et al. Inhibition of hemangiogenesis and lymphangiogenesis after normal-risk corneal transplantation by neutralizing VEGF promotes graft survival. Invest Ophthalmol Vis Sci45, 2666-2673, doi:10.1167/iovs.03-1380 (2004).
7 Shibuya, M. Vascular Endothelial Growth Factor (VEGF) and Its Receptor (VEGFR) Signaling in Angiogenesis: A Crucial Target for Anti- and Pro-Angiogenic Therapies. Genes Cancer2, 1097-1105, doi:10.1177/1947601911423031 (2011).
8 Abdelfattah, N. S. et al. Clinical correlates of common corneal neovascular diseases: a literature review. Int J Ophthalmol8, 182-193, doi:10.3980/j.issn.2222-3959.2015.01.32 (2015).
9 Darcq, E. & Kieffer, B. L. Opioid receptors: drivers to addiction? Nat Rev Neurosci19, 499-514, doi:10.1038/s41583-018-0028-x (2018).
10 Kieffer, B. L. & Gavériaux-Ruff, C. Exploring the opioid system by gene knockout. Prog Neurobiol66, 285-306, doi:10.1016/s0301-0082(02)00008-4 (2002).
11 Dietis, N., Rowbotham, D. J. & Lambert, D. G. Opioid receptor subtypes: fact or artifact? Br J Anaesth107, 8-18, doi:10.1093/bja/aer115 (2011).
12 Piercey, M. F., Lahti, R. A., Schroeder, L. A., Einspahr, F. J. & Barsuhn, C. U-50488H, a pure kappa receptor agonist with spinal analgesic loci in the mouse. Life Sci31, 1197-1200, doi:10.1016/0024-3205(82)90341-1 (1982).
13 Nagase, H. et al. Discovery of a structurally novel opioid kappa-agonist derived from 4,5-epoxymorphinan. Chem Pharm Bull (Tokyo)46, 366-369, doi:10.1248/cpb.46.366 (1998).
14 Kawai, K. et al. Design, synthesis, and structure-activity relationship of novel opioid kappa-agonists. Bioorg Med Chem16, 9188-9201, doi:10.1016/j.bmc.2008.09.011 (2008).
15 Togashi, Y. et al. Antipruritic activity of the kappa-opioid receptor agonist, TRK-820. Eur J Pharmacol435, 259-264, doi:10.1016/s0014-2999(01)01588-6 (2002).
16 Yamamizu, K. et al. к Opioids inhibit tumor angiogenesis by suppressing VEGF signaling. Sci Rep3, 3213, doi:10.1038/srep03213 (2013).
17 Inui, S. Nalfurafine hydrochloride to treat pruritus: a review. Clin Cosmet Investig Dermatol8, 249-255, doi:10.2147/ccid.S55942 (2015).
18 Pan, Q. et al. Blocking neuropilin-1 function has an additive effect with anti-VEGF to inhibit tumor growth. Cancer Cell11, 53-67, doi:10.1016/j.ccr.2006.10.018 (2007).
19 Inomata, T. et al. Corneal Tissue From Dry Eye Donors Leads to Enhanced Graft Rejection. Cornea37, 95-101, doi:10.1097/ICO.0000000000001400 (2018).
20 Lin, Y. J., Lai, M. D., Lei, H. Y. & Wing, L. Y. Neutrophils and macrophages promote angiogenesis in the early stage of endometriosis in a mouse model. Endocrinology147, 1278-1286, doi:10.1210/en.2005-0790 (2006).
21 Inomata, T. et al. Novel immunotherapeutic effects of topically administered ripasudil (K-115) on corneal allograft survival. Sci Rep10, 19817, doi:10.1038/s41598-020-76882-w (2020).
22 Afsaneh Amouzegar, S. K. C., Reza Dana. Alloimmunity and tolerance in corneal transplantation. Journal of immunologyIn press (2016).
23 Tahvildari, M., Inomata, T., Amouzegar, A. & Dana, R. Regulatory T Cell Modulation of Cytokine and Cellular Networks in Corneal Graft Rejection. Curr Ophthalmol Rep6, 2Am 6-274, doi:https://doi.org/10.1007/s40135-018-0191-2 (2018).
24 Inomata, T. et al. Perlecan-deficient mutation impairs corneal epithelial structure. Invest Ophthalmol Vis Sci53, 1277-1284, doi:10.1167/iovs.11-8742 (2012).
25 Zambelli, V. O. et al. Peripheral sensitization increases opioid receptor expression and activation by crotalphine in rats. PloS one9, e90576, doi:10.1371/journal.pone.0090576 (2014).
26 Yanni, S. E., McCollum, G. W. & Penn, J. S. Genetic deletion of COX-2 diminishes VEGF production in mouse retinal Müller cells. Exp Eye Res91, 34-41, doi:10.1016/j.exer.2010.03.019 (2010).
27 Bruchas, M. R. & Chavkin, C. Kinase cascades and ligand-directed signaling at the kappa opioid receptor. Psychopharmacology (Berl)210, 137-147, doi:10.1007/s00213-010-1806-y (2010).
28 Chen, D. et al. Down-regulation of the tumour suppressor κ-opioid receptor predicts poor prognosis in hepatocellular carcinoma patients. BMC Cancer17, 553, doi:10.1186/s12885-017-3541-9 (2017).
29 Yamamizu, K. et al. The kappa opioid system regulates endothelial cell differentiation and pathfinding in vascular development. Blood118, 775-785, doi:10.1182/blood-2010-09-306001 (2011).
30 Yamamizu, K., Hamada, Y. & Narita, M. kappa Opioid receptor ligands regulate angiogenesis in development and in tumours. Br J Pharmacol172, 268-276, doi:10.1111/bph.12573 (2015).
31 Inomata, T., Hua, J., Di Zazzo, A. & Dana, R. Impaired Function of Peripherally Induced Regulatory T Cells in Hosts at High Risk of Graft Rejection. Sci Rep6, 39924, doi:10.1038/srep39924 (2016).
32 Di Zazzo, A. et al. Variable Responses to Corneal Grafts: Insights from Immunology and Systems Biology. Journal of Clinical Medicine9, doi:10.3390/jcm9020586 (2020).
33 Gan, L., Fagerholm, P. & Palmblad, J. Vascular endothelial growth factor (VEGF) and its receptor VEGFR-2 in the regulation of corneal neovascularization and wound healing. Acta Ophthalmol Scand82, 557-563, doi:10.1111/j.1600-0420.2004.00312.x (2004).
34 Di Zazzo, A. et al. Proangiogenic Function of T Cells in Corneal Transplantation. Transplantation101, 778-785, doi:10.1097/TP.0000000000001390 (2017).
35 Yamamizu, K. et al. The κ opioid system regulates endothelial cell differentiation and pathfinding in vascular development. Blood118, 775-785, doi:10.1182/blood-2010-09-306001 (2011).
36 Inomata, T. et al. Kinetics of Angiogenic Responses in Corneal Transplantation. Cornea36, 491-496, doi:10.1097/ICO.0000000000001127 (2017).
37 Yamamizu, K., Hamada, Y. & Narita, M. κ Opioid receptor ligands regulate angiogenesis in development and in tumours. Br J Pharmacol172, 268-276, doi:10.1111/bph.12573 (2015).
38 Abdelfattah, N. S., Amgad, M. & Zayed, A. A. Host immune cellular reactions in corneal neovascularization. Int J Ophthalmol9, 625-633, doi:10.18240/ijo.2016.04.25 (2016).
39 Clements, J. L. & Dana, R. Inflammatory corneal neovascularization: etiopathogenesis. Semin Ophthalmol26, 235-245, doi:10.3109/08820538.2011.588652 (2011).
40 Hua, J. et al. Graft Site Microenvironment Determines Dendritic Cell Trafficking Through the CCR7-CCL19/21 Axis. Invest Ophthalmol Vis Sci57, 1457-1467, doi:10.1167/iovs.15-17551 (2016).
41 Amouzegar, A., Chauhan, S. K. & Dana, R. Alloimmunity and Tolerance in Corneal Transplantation. Journal of immunology196, 3983-3991, doi:10.4049/jimmunol.1600251 (2016).
42 Stein, C. Opioids, sensory systems and chronic pain. Eur J Pharmacol716, 179-187, doi:10.1016/j.ejphar.2013.01.076 (2013).
43 Kieffer, B. L. & Gaveriaux-Ruff, C. Exploring the opioid system by gene knockout. Prog Neurobiol66, 285-306, doi:10.1016/s0301-0082(02)00008-4 (2002).
44 Suzuki, T. et al. Effect of repeated administration of TRK-820, a kappa-opioid receptor agonist, on tolerance to its antinociceptive and sedative actions. Brain Res995, 167-175, doi:10.1016/j.brainres.2003.09.057 (2004).
45 Beck, T. C., Hapstack, M. A., Beck, K. R. & Dix, T. A. Therapeutic Potential of Kappa Opioid Agonists. Pharmaceuticals (Basel)12, doi:10.3390/ph12020095 (2019).
46 Suryawanshi, A. et al. Ocular neovascularization caused by herpes simplex virus type 1 infection results from breakdown of binding between vascular endothelial growth factor A and its soluble receptor. Journal of immunology186, 3653-3665, doi:10.4049/jimmunol.1003239 (2011).
47 Inomata T, Mashaghi A, Di Zazzo A & R., D. Ocular surgical models for immune and angiogenic responses. J Biol Methods2(3):e27, doi:10.14440/jbm.2015.78 (2015).
48 Ogawa M, Inomata T, Shiang T, Tsubota K & Murakami, A. Method for selective quantification of immune and inflammatory cells in the cornea using flow cytometry. J Biol Methods5, e102, doi:10.14440/jbm.2018.237 (2018).
49 Hua, J. et al. The resolvin D1 analogue controls maturation of dendritic cells and suppresses alloimmunity in corneal transplantation. Invest Ophthalmol Vis Sci55, 5944-5951, doi:10.1167/iovs.14-14356 (2014).
50 Inomata, T. A New Immunotherapy Using Regulatory T-Cells for High-Risk Corneal Transplantation. Juntendo Medical Journal63, 2-7, doi:10.14789/jmj.63.2 (2017).